ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Add as a preferred source on Google
Bristol Myers Squibb acquired RayzeBio for a staggering amount of $4.1 billion. The global biopharmaceutical company is investing to bolster its cancer therapy portfolio and business.
Terms of the Agreement
This Bristol Myers Squibb deal is the latest one that it has signed in less than a week. It has just announced its purchase of Karuna Therapeutics, a drug developer, on Friday, as per Reuters.
With the buyout deal, Bristol Myers will have access to RayzeBio's drug production facility located in Indianapolis, Indiana. It was agreed that the former would pay $62.50 in cash for every share of RayzeBio.
Looking Forward to Growth as Bristol Myers and RayzeBio Merge
Bristol Myers Squibb's acquisition of RayzeBio is a strategic move that aligns with the recent gush of mergers and acquisition agreements in the pharmaceutical industry. The companies' respective management teams believe this deal will fuel growth within the second half of this decade.
"This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth opportunities in the back half of the decade and beyond," Bristol Myers Squibb's chief executive officer, Christopher Boerner, Ph.D., said in a press release. "We look forward to supporting and accelerating RayzeBio's preclinical and clinical programs and advancing its highly innovative radiopharmaceutical platform."
RayzeBio's president and CEO, Ken Song, M.D., further stated, "Despite therapeutic advances in recent years, the need for more effective treatments in solid tumors persists, and radiopharmaceutical therapeutics are positioned to be an important next wave of innovation in oncology therapy."
The biotech firm's chief added, "Bristol Myers Squibb's well-established presence in oncology and deep expertise in developing, commercializing, and manufacturing treatments on a global scale makes it the ideal partner for RayzeBio at this important moment in our evolution and I am very excited to see what our team clinches as part of Bristol Myers Squibb."
Photo by: Bristol Myers Squibb Media Gallery
